Abstract
In the Merriam-Webster dictionary, one definition of the word valid is “well-grounded or justifiable: being at once relevant and meaningful.” Validation is then the process of determining the degree of validity. From this broad definition, it follows that validations can be made in many different fields with quite different implications. When talking about validation, it is therefore important to specify the subject under scrutiny and in this chapter the focus will be on validation of biomarkers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95
Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A et al (1992) Analytical methods validation: bioavailabilitybioequivalence and pharmacokinetic studies pharmaceutical research. J Pharm Sci 9(4):588–592
Guidance for Industry (2001) Bioanalytical method validation. Fed Reg 66:28526–28527
Guidance for Industry (2018) Bioanalytical method validation. Fed Reg 83:23690–23691
ISO 15189:2012 (2012) Medical laboratories—Requirements for quality and competence
Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn L, Blennow K, Chiasserini D, Engelborghs S et al (2015) A practical guide to immunoassay method validation. Front Neurol 6:179
Chau CH, Rixe O, McLeod H, Figg WD (2008) Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 14(19):5967–5976
Cullen VC, Fredenburg RA, Evans C, Conliffe PR, Solomon ME (2012) Development and advanced validation of an optimized method for the quantitation of Abeta42 in human cerebrospinal fluid. AAPS J 14(3):510–518
DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B et al (2003) Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 20(11):1885–1900
Findlay JW, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS et al (2000) Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 21(6):1249–1273
Khan MU, Bowsher RR, Cameron M, Devanarayan V, Keller S, King L et al (2015) Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. Bioanalysis 7(2):229–242
Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S et al (2006) Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23(2):312–328
EMA (2011) Guideline on bioanalytical method validation
CLSI (2018) [Collection of standards]. www.clsi.org
Sittampalam GS, Smith WC, Miyakawa TW, Smith DR, McMorris C (1996) Application of experimental design techniques to optimize a competitive ELISA. J Immunol Methods 190(2):151–161
ISO 5725-2 (1994) Accuracy (trueness and precision) of measurement methods and results—Part 2: basic method for the determination of repeatability and reproducibility of a standard measurement method
ISO 5725-4 (1994) Accuracy (trueness and precision) of measurement methods and results—Part 4: basic methods for the determination of the trueness of a standard measurement method
Westgard JO, Barry PL, Hunt MR, Groth T (1981) A multi-rule Shewhart chart for quality control in clinical chemistry. Clin Chem 27(3):493–501
Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H (2015) Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 36(5):297–309
Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H et al (2001) Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease. Ann Neurol 50(2):150–156
Sato C, Barthelemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J et al (2018) Tau kinetics in neurons and the human central nervous system. Neuron 98(4):861–864
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Andreasson, U., Blennow, K., Zetterberg, H. (2021). Method and Clinical Validation of Biomarkers for Neurodegenerative Diseases. In: Teunissen, C.E., Zetterberg, H. (eds) Cerebrospinal Fluid Biomarkers. Neuromethods, vol 168. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1319-1_10
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1319-1_10
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1318-4
Online ISBN: 978-1-0716-1319-1
eBook Packages: Springer Protocols